

News Release

Sobera Capital Acquires International Portfolio of Direct Interests from Innoveas

Berlin, 26 February, 2018 - Sobera Capital has acquired a portfolio of 12 minority and majority equity holdings in private companies mainly in the life sciences sector from Innoveas International Ltd. The assets, which include, among others, interests in Presidio Pharmaceuticals, EffRx Pharmaceuticals, M.O.R.E. Medical Solutions, Axellis Ventures and MyoScience, are based mainly in Europe and the US. Sobera Capital was backed in this secondary direct transaction by several family offices and entrepreneurs.

Sobera Capital is a Berlin based independent secondary direct investor with a focus on growth and small-cap funds and assets in T.I.M.E.S, healthcare and selected other industries.

Find more information at www.sobera-capital.com.

Innoveas is a business which is unique in building game-changing companies from world class technologies developed by public research. Its business is focused on the health and the energy sectors.

Contact

Dr. Stefan Beil		
Sobera Capital GmbH	T	+49 (0)30 57 70 88 - 372
Markgrafenstr. 33	F	+49 (0)30 57 70 88 - 379
D-10117 Berlin	E	sbeil@sobera-capital.com
Germany	W	www.sobera-capital.com